Corticotropin releasing factor 2 receptor agonists
View Patent ↗Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.
1. A non-native peptide according to formula:
IVLSLDVPIGLLQILLEQX 19 KX 21 X 22 X 23 X 24 X 25 X 26 QATTNARILARV (SEQ ID NO: 531)
wherein:
(a) X 19 is selected from the group consisting of D and E;
(b) X 21 is selected from the group consisting of A and Q;
(c) X 22 is selected from the group consisting of R, E, and K;
(d) X 23 is selected from the group consisting of A, K, and N;
(e) X 24 is selected from the group consisting of A, E, and L;
(f) X 25 is selected from the group consisting of R and K; and
(g) X 26 is selected from the group consisting of E and Q.
2. The peptide of claim 1 , wherein X 19 is D.
3. The peptide claim 1 , wherein X 21 is A.
4. The peptide of claim 1 , wherein X 22 is R.
5. The peptide of claim 1 , wherein X 22 is E.
6. The peptide of claim 1 , wherein X 23 is A.
7. The peptide of claim 1 , wherein X 23 is K.
8. The peptide of claim 1 , wherein X 24 is A.
9. The peptide of claim 1 , wherein X 24 is E.
10. The peptide of claim 1 , wherein X 25 is R.
11. The peptide of claim 1 , wherein X 26 is E.
12. A method of preventing or treating a CRF 2 R modulated disorder comprising administering to a host in need of such treatment a safe and effective amount of a peptide of claim 1 .
13. The method according to claim 12 , wherein the CRF 2 R modulated disorder is skeletal muscle atrophy or muscular dystrophy.
14. A pharmaceutical composition comprising:
(a) a safe and effective amount of a peptide of claim 1 ; and
(b) a pharmaceutically acceptable carrier.
15. A kit for preventing or treating a CRF 2 R modulated disorder comprising:
(a) a peptide of claim 1 in a unit dose form; and
(b) usage instruction.
16. A peptide having the amino acid sequence of SEQ ID NO: 121.
17. A method of preventing or treating a CRF 2 R modulated disorder comprising administering to a mammal in need of such treatment a safe and effective amount of a peptide of claim 16 .
18. The method according to claim 17 , wherein the CRF 2 R modulated disorder is skeletal muscle atrophy or muscular dystrophy.
19. A pharmaceutical composition comprising:
(a) a safe and effective amount of a peptide of claim 16 ; and
(b) a pharmaceutically acceptable carrier.
20. A kit for preventing or treating a CRF 2 R modulated disorder comprising:
(a) a peptide of claim 16 in a unit dose form; and
(b) usage instruction.